WO2022106851A1 - Mebendazole pour une utilisation dans le traitement de la polykystose rénale autosomique dominante ou de la polykystose rénale autosomique récessive - Google Patents

Mebendazole pour une utilisation dans le traitement de la polykystose rénale autosomique dominante ou de la polykystose rénale autosomique récessive Download PDF

Info

Publication number
WO2022106851A1
WO2022106851A1 PCT/GB2021/053020 GB2021053020W WO2022106851A1 WO 2022106851 A1 WO2022106851 A1 WO 2022106851A1 GB 2021053020 W GB2021053020 W GB 2021053020W WO 2022106851 A1 WO2022106851 A1 WO 2022106851A1
Authority
WO
WIPO (PCT)
Prior art keywords
mebendazole
composition
adpkd
treatment
arpkd
Prior art date
Application number
PCT/GB2021/053020
Other languages
English (en)
Inventor
Phil BROWNJOHN
Original Assignee
Healx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Healx Ltd filed Critical Healx Ltd
Publication of WO2022106851A1 publication Critical patent/WO2022106851A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Definitions

  • This invention relates to new uses of mebendazole.
  • ADPKD Autosomal dominant polycystic kidney disease
  • hepatic cysts and subarachnoid hemorrhage vary in frequency and severity between patients.
  • PKD1 and PKD2 encode the polycystin proteins, PCI and PC2, respectively, which - form a core complex in the primary cilium of renal epithelial cells and regulate intracellular signalling pathways. However, these become dysregulated upon ADPKD-associated mutations.
  • ADPKD ADPKD-related diseases
  • An existing medication that is indicated to slow kidney function decline in adults at risk of rapidly progressing ADPKD is tolvaptan, however this drug is known to have common and occasionally severe side effects, such as liver injury.
  • ARPKD Autosomal recessive polycystic kidney disease
  • ADPKD Autosomal recessive polycystic kidney disease
  • ARPKD is also characterized by multiple fluid-filled renal cysts which appear in utero and expand to cause enlarged kidneys.
  • the disease course is much more severe, with many patients who survive the neonate period progressing to end stage renal disease by late childhood or early adulthood. Extrarenal manifestations are common, and can be severe, with pulmonary hypoplasia claiming approximately 30% of ARPKD patients in the neonatal period, and hepatic fibrosis occurring in many patients with varying severity.
  • PKHD1 encodes the protein fibrocystin, which localises to the primary cilium of renal epithelial cells. While the function of fibrocystin has not been completely elucidated, it has been shown to interact with the ciliary PC1/PC2 complex implicated in ADPKD, and a number of the same intracellular pathways driving cyst growth are shared between ARPKD and ADPKD. This suggests that therapies targeting disease progression through the inhibition of cyst growth may be effective in both conditions.
  • Mebendazole is a broad spectrum benzimidazole anthelmintic that is used in humans and animals for the treatment of various parasitic infections, including those caused by Whipworm, Hookworm, Roundworm, Tapeworm and Threadworm. Its primary mode of action in parasites is via binding to the colchicine-sensitive site of tubulin, thus blocking polymerisation and subsequent microtubule formation, leading to impaired uptake of glucose, a reduced production of energy, and eventually paralysis and death. The selective toxicity of mebendazole is thought to be due to a higher affinity for parasitic over mammalian tubulin targets. Mebendazole has the systematic name (5-benzoyl-lH- benzimidazol-2-yl)carbamic acid methyl ester.
  • the present invention is a composition comprising mebendazole, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of ADPKD and ARPKD.
  • mebendazole is effective in treating and preventing ADPKD and ARPKD.
  • a first aspect of the invention is a composition comprising mebendazole, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of ADPKD or ARPKD.
  • a second aspect of the invention is use of mebendazole, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment or prevention of ADPKD or ARPKD.
  • a third aspect of the invention provides a method of treating or preventing ADPKD or ARPKD comprising administering the patient with a composition comprising mebendazole or a pharmaceutically acceptable salt thereof.
  • Figure 1 shows the results of mebendazole on cyst growth and cell death in the absence of a ddAVP stimulus in in vitro ADPKD assays.
  • Figure 2 shows the results of mebendazole on cyst growth and cell death in the presence of a ddAVP stimulus in in vitro ADPKD assays.
  • Figure 3 shows the results of mebendazole on cyst growth and cell number in the absence and presence of an AVP stimulus in in vitro ARPKD assays
  • Figure 4 shows the results of mebendazole on kidney cyst burden in an animal model of polycystic kidney disease.
  • Figure 5 shows the results of mebendazole on increased kidney weight in an animal model of polycystic kidney disease.
  • Figure 6 shows the results of mebendazole on elevated blood urea levels in an animal model of polycystic kidney disease.
  • mebendazole inhibits the growth of cysts, without causing an increase in cell death, and is therefore effective at treating and preventing ADPKD and ARPKD.
  • ebendazole refers to any one of the solid state forms: polymorph A, polymorph B, polymorph C, or a mixture of polymorphs A, and/or B and/or C.
  • mebendazole refers to mebendazole polymorph A. In another embodiment, mebendazole refers to mebendazole polymorph B. In another embodiment, mebendazole refers to polymorph C.
  • mebendazole refers to a mixture of polymorphs A, and/or B and/or C.
  • the mixture is a mixture of polymorphs A and B, or polymorphs A and C, or polymorphs B and C or polymorphs A, B and C.
  • treatment or “treating” as used herein, we refer to therapeutic (curative) treatment.
  • Treatment also includes stopping the disease from developing or slowing further progression of the disease.
  • treatment may include preventing a cyst from growing bigger or slowing a cyst's growth rate.
  • prevention or “preventing” as used herein, we refer to “prophylactic” treatment, which includes administering mebendazole to a patient that has mutations in the PKD1 and/or PKD2 and/or PKHD1 gene.
  • PKD and ARPKD are highly allelically heterogeneous diseases.
  • the Mayo Clinic PKD database currently lists 1273 pathogenic PKD1 mutations and 202 pathogenic PKD2 mutations, many of which are unique to individual families. As such there are no prototypical common mutations that represent the diseases.
  • the patient has a mutation in the PKD1 gene and/or the PKD2 gene, preferably the mutation is pathogenic.
  • the patient has a mutation in the PKHD1 gene, preferably the mutation is pathogenic.
  • mebendazole is used for the treatment or prevention of ADPKD or ARPKD, wherein the patient has had or is going to have surgery to remove some or all of cysts caused by the ADPKD or ARPKD.
  • This may be particularly advantageous if the cysts are large and/or expands across tissue boundaries, and/or large in number, so it is difficult to remove them all by surgery and/or a quick removal of at least some of it is desired/beneficial.
  • Surgery has its normal meaning in the art. Surgery is an invasive technique with the fundamental principle of physical intervention on organs/organ systems/tissues for diagnostic or therapeutic reasons.
  • a pharmaceutically acceptable salt is a salt with a pharmaceutically acceptable acid or base.
  • the present invention is directed to a composition comprising mebendazole, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of ADPKD or ARPKD.
  • the composition comprising mebendazole, or a pharmaceutically acceptable salt thereof is for use in the treatment or prevention of
  • composition comprising mebendazole, or a pharmaceutically acceptable salt thereof, is for use in the treatment or prevention of ARPKD.
  • the present invention is directed to a composition comprising mebendazole, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of ADPKD or ARPKD, wherein mebendazole is the only active agent in the composition.
  • mebendazole is the only active agent in the composition.
  • only active agent it is meant that the composition does not contain other components which may be used in the treatment or prevention of ADPKD or ARPKD.
  • compositions of the invention may contain a pharmaceutically acceptable carrier.
  • pharmaceutically acceptable carrier is meant any diluent or excipient, such as fillers or binders, that is compatible with the other ingredients of the composition, and which is not deleterious to the recipient.
  • the pharmaceutically acceptable carrier can be selected on the basis of the desired route of administration, in accordance with standard pharmaceutical practices.
  • the composition may be administered in a variety of dosage forms.
  • the composition may be formulated in a format suitable for oral, rectal, parenteral, intranasal or transdermal administration or administration by inhalation or by suppository.
  • the composition may be administered orally, for example as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules.
  • the composition is formulated such that it is suitable for oral administration, for example tablets and capsules.
  • Tablets and capsules may be prepared with binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, celluloses or polyvinylpyrrolidone; fillers, such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine; lubricants, such as magnesium stearate, talc, polyethylene glycol, or silica; and surfactants, such as sodium lauryl sulfate.
  • binding agents for example, syrup, acacia, gelatin, sorbitol, tragacanth, celluloses or polyvinylpyrrolidone
  • fillers such as lactose, sucrose, corn starch, calcium phosphate, sorbitol, or glycine
  • lubricants such as magnesium stearate, talc, polyethylene glycol, or silica
  • surfactants such as sodium lauryl sulfate.
  • Liquid compositions may contain conventional additives such as suspending agents, for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethyl-cellulose, or edible fats; emulsifying agents and surfactants such as lecithin, or acacia; vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil; preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
  • suspending agents for example sorbitol syrup, methyl cellulose, sugar syrup, gelatin, carboxymethyl-cellulose, or edible fats
  • emulsifying agents and surfactants such as lecithin, or acacia
  • vegetable oils such as almond oil, coconut oil, cod liver oil, or peanut oil
  • preservatives such as butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
  • Liquid compositions may be encapsulated in, for example,
  • composition may also be administered parenterally, whether intraperitoneally, subcutaneously, intravenously, intramuscularly, intrasternally, transdermally or by infusion techniques.
  • the composition may also be administered by inhalation.
  • inhaled medications are their direct delivery to the area of rich blood supply in comparison to many medications taken by oral route. Thus, the absorption is very rapid as the alveoli have an enormous surface area and rich blood supply and first pass metabolism is bypassed.
  • the present invention also provides an inhalation device containing the composition of the present invention.
  • said device is a metered dose inhaler (MDI), which contains a pharmaceutically acceptable chemical propellant to push the medication out of the inhaler.
  • MDI metered dose inhaler
  • the composition may also be administered by intranasal administration.
  • the nasal cavity's highly permeable tissue is very receptive to medication and absorbs it quickly and efficiently.
  • Nasal drug delivery is less painful and invasive than injections, generating less anxiety among patients. By this method absorption is very rapid and first pass metabolism is usually bypassed, thus reducing inter-patient variability.
  • the present invention also provides an intranasal device containing the composition according to the present invention.
  • composition may also be administered by transdermal administration.
  • transdermal and transmucosal patches for topical delivery, transdermal and transmucosal patches, creams, ointments, jellies, solutions or suspensions may be employed.
  • the present invention therefore also provides a transdermal patch containing the composition.
  • the composition may also be administered by sublingual administration.
  • the present invention therefore also provides a sub-lingual tablet comprising the composition.
  • the composition may also be formulated with an agent which reduces degradation of the substance by processes other than the normal metabolism of the patient, such as anti-bacterial agents, or inhibitors of protease enzymes which might be the present in the patient or in commensural or parasite organisms living on or within the patient, and which are capable of degrading the compound.
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • Suspensions and emulsions may contain as carrier, for example a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
  • the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and if desired, a suitable amount of lidocaine hydrochloride.
  • Solutions for injection or infusion may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions.
  • the composition is administered in an effective amount to treat or prevent ADPKD or ARPKD.
  • An effective dose will be apparent to one skilled in the art, and is dependent on a number of factors including age, sex, weigh, which the medical practitioner will be capable of determining.
  • the composition comprises 25 to 3500 mg, more preferably 500 to 3000 mg, yet more preferably 1000 to 2600 mg of mebendazole.
  • a single dose of the composition of the invention comprises between 10 mg/kg to 100 mg/kg, preferably 20 mg/kg to 70 mg/kg, more preferably 30 mg/kg to 60 mg/kg, yet more preferably 40 mg/kg to 50 mg/kg of mebendazole based on the subject's weight (kg).
  • the composition is administered at least once a day. Preferably it is administered as a single daily dose.
  • composition may be administered once a day, twice a day, three times a day or four times a day.
  • the single daily dose is 25 to 3500 mg, more preferably 500 to 3000 mg, yet more preferably 1000 to 2600 mg of mebendazole.
  • the composition comprises 12.5 to 1750 mg and is administered twice daily.
  • each dose is 12.5 to 1750 mg, more preferably 250 mg to 1500 mg, yet more preferably 500 mg to 1300 mg of mebendazole.
  • each dose of the composition of the invention administered twice daily comprises between 5 mg/kg to 50 mg/kg, preferably 10 mg/kg to 35 mg/kg, more preferably 15 mg/kg to 30 mg/kg, yet more preferably 20 mg/kg to 25 mg/kg of mebendazole based on the subject's weight (kg).
  • the composition comprises 8 mg to 1170 mg and is administered three times daily.
  • each dose is 8 mg to 1170 mg, more preferably 170 mg to 1000 mg, yet more preferably 330 mg to 870 mg of mebendazole.
  • each dose of the composition of the invention administered thrice daily comprises between 1 mg/kg to 35 mg/kg, preferably 5 mg/kg to 25 mg/kg, more preferably 10 mg/kg to 20 mg/kg of mebendazole based on the subject's weight (kg).
  • the composition comprises 6 mg to 875 mg and is administered four times daily.
  • each dose is 6 mg to 875 mg, more preferably 125 mg to 750 mg, yet more preferably 250 mg to 650 mg of mebendazole.
  • each dose of the composition of the invention administered four times daily comprises between 1 mg/kg to 20 mg/kg, preferably 5 mg/kg to 15 mg/kg, more preferably 8 mg/kg to 13 mg/kg of mebendazole based on the subject's weight (kg).
  • the dosage regime is such that the total daily dosage of mebendazole does not exceed 3500 mg.
  • the composition comprising mebendazole may be used in a chronic dosage regime i.e. chronic, long-term treatment.
  • a chronic dosage regime i.e. chronic, long-term treatment.
  • the regime lasts for at least one month, suitably at least two months, such as at least three months.
  • the present invention also relates to use of mebendazole, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in the treatment or prevention of ADPKD or ARPKD.
  • This embodiment of the invention may have any of the preferred features described above.
  • the present invention also relates to a method of treating or preventing ADPKD or ARPKD comprising administering the patient with a composition comprising mebendazole or a pharmaceutically acceptable salt thereof.
  • This embodiment of the invention may have any of the preferred features described above.
  • the method of administration may be according to any of the routes described above.
  • the present invention also embraces prodrugs which react in vivo to give a compound of the present invention.
  • Example 1 In vitro drug testing utilizing primary ADPKD patient kidney cells
  • Cells were mixed with PrimCyst-Gel (OcellO BV). 15pL of cell-gel mix was pipetted to 384- well plates using a CyBio Felix 96/250 robotic liquid dispenser. Gel-cell mix was plated at a final cell density of 450 objects per well. After gel polymerization at 37°C for 30 minutes, 33pL culture medium was added to each well. Cells were grown in gel for 24 hours, after which the cells were co-exposed or not with the cystogenic stimulus l-deamino-8-D- arginine vasopressin (ddAVP) and one the following molecules: toxic control compound Staurosporine, or mebendazole.
  • ddAVP cystogenic stimulus l-deamino-8-D- arginine vasopressin
  • Imaging was done using Molecular Devices ImageXpress Micro XLS with a 4x NIKON objective. For each well around 35 images in the Z-direction were made for both channels, capturing the whole z-plane in each image. Image analysis was performed using OminerTM software (OcellO BV). Cysts were segmented using detection of Hoechst-stained nuclei and Rhodamine-phalloidin-stained cellular f-actin. Cyst area was determined by calculating for the area in px of each object in every in-focus plain. This was averaged per well. Fraction of dead cells as an indicator of toxicity was calculated as the amount of nuclei without actin signal relative to the total amount of nuclei, both as count-measurements. Cyst area was normalised to DMSO-treated controls, and presented as a Z-score normalised value.
  • Mebendazole had a purity of >95%. After solubilisation in DMSO, mebendazole was tested in an eight point concentration curve in quadruplicate across all three ADPKD patient- derived cell models.
  • results for mebendazole in the absence of ddAVP stimulus can be seen in Figure 1.
  • Mebendazole reduces cyst growth in a concentration-dependent manner without causing an increase in cell death.
  • results for mebendazole in the presence of ddAVP stimulus can be seen in Figure 2.
  • Mebendazole reduces cyst growth to below the level seen in the absence of a cystogenic stimulus (ddAVP) in a concentration-dependent manner without causing an increase in cell death.
  • Mebendazole inhibits the growth of cysts in vitro in three cell models of ADPKD. It is thus expected that mebendazole will reduce, treat and prevent ADPKD.
  • Example 2 In vitro drug testing utilizing primary patient-derived ARPKD kidney cells
  • Primary ARPKD cells were derived from patient kidneys. Patient genotype was determined as PKHD1: p.Leu4037Pro.
  • Cells were cultured in biogels containing RenalCyte media (DiscoveryBiomed) in 384-well plates at a density of 5500 cells/well. The day after plating, cells were co-exposed or not with the cystogenic stimulus arginine vasopressin (AVP), alongside varying concentrations of mebendazole. Additional mebendazole and AVP stimulus was added on culture days 4, 8 and 11.
  • AVP arginine vasopressin
  • results for mebendazole in the ARPKD cell model can be seen in Figure 3.
  • mebendazole inhibits the growth of cysts and the proliferation of cells in a concentration-dependent manner in an ARPKD cell model across 14 days of treatment.
  • Mebendazole inhibits the growth of cysts and proliferation of cells in a cell model of ARPKD.
  • mebendazole will reduce, treat and prevent ARPKD.
  • Example 3 In vivo drug testing using an animal model of polycystic kidney disease
  • Ksp-TamCre x PkdlLox mice on a C57/BL6 background were bred, then housed in their litters in IVC cages from Innovive with sterilized corncob bedding (irradiated, dust-free supplied by Innovive, USA) and a shelter-like device (if feasible; PLEXX, The Netherlands) to stimulate natural patterns of behavior.
  • Animals were maintained at 21°C ⁇ 2°C and a relative humidity between 40 to 70%, on a 12/12 light/dark cycle with air renewed 8-20 times per hour. During the in-life period, the animals had free access to standard pelleted food (Diet No. V1534-703 valid until 05/2020, supplied by SNIFF, Germany) and water.
  • mice were dosed orally on both postnatal days 10 and 11 (PND10 and 11) with 25mg Tamoxifen/kg bodyweight (Pkdl KO).
  • PND10 and 11 postnatal days 10 and 11
  • Pkdl KO 25mg Tamoxifen/kg bodyweight
  • Non- tamoxifen treated mice were used as Pkdl wildtype controls (Pkd1 WT).
  • Mebendazole was formulated in 10% DMSO / 90% HP- ⁇ -CD (20% w/v in water) and dosed by daily intraperitoneal injection (IP) from PND14 to PND27 at 15mg/kg.
  • IP intraperitoneal injection
  • everolimus was formulated in 5% EtOH / 7% PEG400 / 5% Tween80 / 83% water and dosed by daily oral gavage (PO) from PND14 to PND27 at 4mg/kg.
  • Mebendazole treatment ameliorates elevated blood urea levels in polycystic kidney disease
  • Mebendazole reduces kidney cyst burden, ameliorates increased kidney weight, and ameliorates elevated blood urea in an animal model of polycystic kidney disease. It is thus expected that mebendazole will reduce, treat and prevent ADPKD and ARPKD.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition comprenant du mébendazole, ou un sel pharmaceutiquement acceptable de celui-ci, destinée à être utilisée dans le traitement ou la prévention de la polykystose rénale autosomique dominante (ADPKD) ou de la polykystose rénale autosomique récessive (ARPKD).
PCT/GB2021/053020 2020-11-23 2021-11-23 Mebendazole pour une utilisation dans le traitement de la polykystose rénale autosomique dominante ou de la polykystose rénale autosomique récessive WO2022106851A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2018400.8A GB202018400D0 (en) 2020-11-23 2020-11-23 Treatment
GB2018400.8 2020-11-23

Publications (1)

Publication Number Publication Date
WO2022106851A1 true WO2022106851A1 (fr) 2022-05-27

Family

ID=74046975

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2021/053020 WO2022106851A1 (fr) 2020-11-23 2021-11-23 Mebendazole pour une utilisation dans le traitement de la polykystose rénale autosomique dominante ou de la polykystose rénale autosomique récessive

Country Status (2)

Country Link
GB (1) GB202018400D0 (fr)
WO (1) WO2022106851A1 (fr)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LARSEN ANDREW R. ET AL: "Repurposing the Antihelmintic Mebendazole as a Hedgehog Inhibitor", MOLECULAR CANCER THERAPEUTICS, vol. 14, no. 1, 5 November 2014 (2014-11-05), US, pages 3 - 13, XP055881248, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-14-0755-T *
SILVA LUCIANE M. ET AL: "Inhibition of Hedgehog signaling suppresses proliferation and microcyst formation of human Autosomal Dominant Polycystic Kidney Disease cells", SCIENTIFIC REPORTS, vol. 8, no. 1, 21 March 2018 (2018-03-21), XP055881258, Retrieved from the Internet <URL:http://www.nature.com/articles/s41598-018-23341-2> DOI: 10.1038/s41598-018-23341-2 *
TRAN PAMELA V. ET AL: "Downregulating Hedgehog Signaling Reduces Renal Cystogenic Potential of Mouse Models", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, vol. 25, no. 10, 3 April 2014 (2014-04-03), US, pages 2201 - 2212, XP055881270, ISSN: 1046-6673, DOI: 10.1681/ASN.2013070735 *

Also Published As

Publication number Publication date
GB202018400D0 (en) 2021-01-06

Similar Documents

Publication Publication Date Title
KR101918669B1 (ko) 신경 장애 치료용 신규 조성물
KR20210137466A (ko) 담즙정체성 간 질환을 갖는 소아 대상체에서 성장을 증가시키는 방법
US20080058303A1 (en) Use of melagatran
EA021303B1 (ru) Способы лечения или профилактики рвоты с помощью агентов, усиливающих секрецию гормона роста
CN116712423A (zh) 治疗特定患者群体的神经变性病症的方法
WO2014124396A1 (fr) Stratégies thérapeutiques pour traiter la pré-éclampsie
AU2018392987A1 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
PT2086535E (pt) Antagonista do receptor de angiotensina ii para o tratamento de doenças sistémicas em gatos
KR20170045353A (ko) 요실금 예방용 및/또는 치료용의 신규한 의약 조성물
TWI472519B (zh) 含正－亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能
WO2022106851A1 (fr) Mebendazole pour une utilisation dans le traitement de la polykystose rénale autosomique dominante ou de la polykystose rénale autosomique récessive
WO2018151285A1 (fr) Médicament pour la prévention ou le traitement des maladies de peau s&#39;accompagnant de prurit
US11396510B2 (en) GABAA receptor ligand
KR20240012533A (ko) 자가면역, 동종면역, 염증성 및 미토콘드리아 질환 치료용 조성물 및 이의 용도
CN109069450A (zh) 神经障碍的新的组合疗法
US10143666B2 (en) Small molecule inhibitors targeting CAG-repeat RNA toxicity in polyglutamine diseases
AU2019365117A1 (en) Sildenafil for use in the treatment of osteoarthritis
US20220370412A1 (en) Inhibition of neurological injuries due to infections via administration of butanetap and analogs thereof
US20230310342A1 (en) Osteogenic agents and uses thereof
RU2799049C2 (ru) Способы лечения изменений поведения
Simmons 5-Ht1f receptor agonism for the treatment of spinal cord injury
CN101631538B (zh) 用于治疗慢性阻塞性肺病的药物
WO2024033946A1 (fr) Compositions et utilisation dans des méthodes de traitement d&#39;un déficit cognitif
WO2023278684A1 (fr) Compositions et méthodes de traitement de la dysferlinopathie
KR20190031122A (ko) 폴마콕시브 및 트라마돌을 포함하는 급, 만성 통증 치료용 약제학적 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21819183

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21819183

Country of ref document: EP

Kind code of ref document: A1